SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

STEVENSON, Md.--()--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Arrowhead Research Corp. (“Arrowhead” or the “Company”) (Nasdaq: ARWR) common stock during the period between August 12, 2014 and October 8, 2014, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until December 9, 2014 to seek appointment as lead plaintiff.

If you have suffered a loss from investment in Arrowhead common stock purchased on or after August 12, 2014 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at: http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period the true efficacy of its experimental hepatitis B therapy ARC-520. According to the complaint, following the Company’s October 8, 2014 release of disappointing data from its experimental hepatitis B therapy ARC-520 and following an article published on TheStreet.com on the same date reporting that Arrowhead CEO Chris Anzalone and his team falsely led investors to believe that ARC-520 was more potent than it actually was, the value of Arrowhead shares declined significantly.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contacts

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com

Contacts

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com